Determination of Genotoxic alkyl p-toluene Sulfonates in Cabazitaxel using LC-MS Method

Author(s): Bavireddi Mohan*, Ramayanam Siva Kameswara Sharma, Devarakonda Ravi Kumar, Seshagiri Vijaya Murali Mohan Rao, Nutulapati Venkata Satya Venugopal.

Journal Name: Current Pharmaceutical Analysis

Volume 15 , Issue 7 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Introduction: A suitable LC-MS method for the quantitative determination of genotoxic impurities such as alkyl p-toluene sulfonates in Cabazitaxel was developed. Alkyl p-toluene sulfonates were estimated by LC-MS method using Waters Symmetry C18 (75×4.6 mm), 3.5 µ column.

Materials and Methods: Column temperature was maintained 40 °C. Injection volume was 10 µL and flow rate was set as 0.8 mL/min. Sampler temperature was maintained to 25 °C and run time was set as 25 minutes. The mobile phase was a mixture of ammonium acetate buffer and acetonitrile in 70:30(v/v) was used.

Results: The method validation has been carried as per ICH guidelines. LOQ was found to be 2.66 µg/mL, 2.75 µg/mL and 2.55 µg/mL for MPTS, EPTS and IPPTS Alkyl p-Toluene Sulfonates (APTS) respectively.

Conclusion: The proposed Liquid chromatography-Mass spectroscopy method that can quantify genotoxic APTS in Cabazitaxel at low-level concentration has been developed and validated as per ICH guidelines. Hence, the proposed method was recommended for the assay of genotoxic impurities of cabazitaxel in dosage forms in busy pharmaceutical laboratories.

Keywords: Genotoxic impurities, cabazitaxel, Liquid Chromatography-Mass Spectrometry (LC-MS) validation, limit of quantitation, alkyl p-toluene, cancer.

[1]
Cheetham, P.; Petrylak, D.P. Tubulin-targeted agents including docetaxel and cabazitaxel. Cancer J., 2013, 19(1), 59-65.
[http://dx.doi.org/10.1097/PPO.0b013e3182828d38] [PMID: 23337758]
[2]
Assessment report for Jevtana (Cabazitaxel), Procedure no.: EMEA/H/C/002018. In: ; European Medicines Agency: London, 2011.
[3]
Jevtana (Cabazitaxel) injection approved by U.S. FDA after priority review” (Press release). Sanofi-Aventis., 2010.
[4]
Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4(4), 253-265.
[http://dx.doi.org/10.1038/nrc1317] [PMID: 15057285]
[5]
Oudard, S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol., 2011, 7(4), 497-506.
[http://dx.doi.org/10.2217/fon.11.23] [PMID: 21463139]
[6]
Pivot, X.; Koralewski, P.; Hidalgo, J.L.; Chan, A.; Gonçalves, A.; Schwartsmann, G.; Assadourian, S.; Lotz, J.P. A multicenter phase II study of XRP6258 administered as a 1-H I.V. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol., 2008, 19(9), 1547-1552.
[http://dx.doi.org/10.1093/annonc/mdn171] [PMID: 18436520]
[7]
Kishore, G. New spectrophotometric methods for the quantitative estimation of Cabazitaxel in formulations. Int. J. Res. Rev. Pharm. Applied Sci., 2012, 2(5), 950-958.
[8]
Li, C.; Lan, G.; Jiang, J.; Sun, M.; Hang, T. Development and validation of a stability indicating HPLC method for the determination of the impurities in Cabazitaxel. Chromatographia, 2015, 78, 825-831.
[http://dx.doi.org/10.1007/s10337-015-2900-4]
[9]
Annapurna, M.M.; Pramadvara, K.; Venkatesh, B.; Sowjanya, G. Stability indicating RP-HPLC method for the determination of Cabazitaxel, Indo American. J. Pharm. Res., 2013, 3(11), 9262-9269.
[10]
Annapurna, M.M.; Venkatesh, B.; Naga Supriya, G. A validated stability-indicating liquid chromatographic method for determination of Cabazitaxel-A novel microtubule inhibitor. J. Bioequivalence Bioavailab., 2014, 6(4), 134-138.
[11]
Annapurna, M.M.; Venkatesh, B.; Pramadvara, K.; Hemchand, S. Development and validation of a stability indicating liquid chromatographic method for the assay of Cabazitaxel. Chem. Sci. Trans., 2014, 3(2), 854-860.
[12]
Patrol, J.V.; Rao, N.R.; Tripathy, N.K. LC-MS/MS determination of Cabazitaxel in rat whole blood on dry blood Spots. Open Access. Sci. Rep., 2012, 1(6), 1-4.
[13]
Kort, A.; Hillebrand, M.J.X.; Cirkel, G.A.; Voest, E.E.; Schinkel, A.H.; Rosing, H.; Schellens, J.H.; Beijnen, J.H. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2013, 925, 117-123.
[http://dx.doi.org/10.1016/j.jchromb.2013.02.034] [PMID: 23542607]
[14]
De Brujin, P.; de Graan, A-J.M.; Nieuweboer, A.; Ron, H.J.M.; Lam, M-H.; de Wit, R.; Wiemer, E.A.C.; Loos, W.J. Quantification of Cabazitaxel in human plasma by liquid chromatography/triple quadrupole mass spectrometry: A practical solution for non-specific binding. J. Pharm. Biomed. Anal., 2012, 59, 117-122.
[http://dx.doi.org/10.1016/j.jpba.2011.10.010]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 7
Year: 2019
Page: [753 - 761]
Pages: 9
DOI: 10.2174/1573412915666190522085818
Price: $65

Article Metrics

PDF: 26
HTML: 2
EPUB: 1
PRC: 1

Special-new-year-discount